Q1 2026 IRLAB Therapeutics AB Earnings Call Transcript

May 6, 2026 / 08:00 AM GMT

Transcript

Key Points

Positve

IRLAB Therapeutics AB (OSTO:IRLAB A) reported a positive cash flow from operating activities amounting to 34 million.
The company has initiated several promising projects, including a new chemical entity in the levodopa industry.
IRLAB Therapeutics AB has started patent production, indicating a focus on protecting intellectual property.
The company is actively engaging in partnerships, which could enhance its research and development capabilities.
There is a focus on groundbreaking products for Parkinson's disease, which could position the company as a leader in this therapeutic area.

Negative

The earnings call transcript indicates some challenges with cash flow management, particularly in relation to partnering costs.
There are concerns about the company's ability to maintain a steady cash flow, as indicated by the need for additional financing.
The transcript suggests potential delays in project timelines, which could impact future revenue streams.
There is a mention of negative consequences related to certain projects, which could pose risks to the company's operations.
The company's reliance on partnerships may expose it to risks if these partnerships do not yield the expected results.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IRLABa.ST - IRLAB Therapeutics AB
Q1 2026 IRLAB Therapeutics AB Earnings Call
May 06, 2026 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Kvartal's presentation. E-Lab Therapeutics of Forskakvartal and Sugisius sex.

Kristina Tolfgord, Nicholas Waters, Senior Vice President, R&D. Gustav Albert, CFO. Comment at present here at the activity at the OC defaults over in Frogeston. Me analytic here at the Industrial Frogur. Welcome.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, comrade Nora Hembelser. So my hand on the period...

After the period......................

I hope Nicholas Walters' comrades to present here. What's on my hand? I'm going to check them. I

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.